Batlevi C. L.from the Memorial Sloan Kettering Cancer Center(MSKCC) and colleagues reported a phase II of entinostat in 49 heavily pre-treated Hodgkin Lymphoma (HL) patients. This study was published in Haematologica in August 2016.
They treated 33 patients with oral entinostat once every other week (schedule A) and 16 patients once weekly in 3 of 4 weeks (schedule B). Their key findings were:
- ITT ORR = 12%
- ITT Disease control (CR + PR + SD >6 months) = 24% (27% schedule A and 19% schedule B)
- Median follow-up of 27.9 months: mPFS = 3.8 months and mOS = 24.6 months
- The main toxicity was hematologic with the most common grade 3-4 AEs being thrombocytopenia (63%), anemia (47%), neutropenia (41%), leukopenia (10%) and extra-hematological toxicity (hypokalemia and hypophosphatemia) was <10%
- Dose modifications (decrease or delay) were performed in 51% patients
The results of the phase II ENGAGE-501 demonstrated clinical efficacy and a manageable toxicity profile of entinostat, a new HDAC inhibitor, in a heavily pre-treated HL population. These results seem encouraging for future treatment combinations of HDAC inhibitors with checkpoint inhibitors and have highlighted a potential synergistic effect between the two drug classes.
ENGAGE- 501: phase II study of entinostat (SDNX-275) in relapsed and refractory Hodgkin lymphoma
Connie Lee Batlevi et al.
Classical Hodgkin lymphoma treatment is evolving rapidly with high response rates from antibody-drug conjugates targeting CD30 and immune checkpoint antibodies. However, most patients do not achieve a complete response, therefore development of novel therapies is warranted to improve patient outcomes. In this phase II study, patient with relapsed or refractory Hodgkin lymphoma were treated with entinostat, an isoform selective histone deacetylase inhibitor. Forty-nine patients were enrolled: 33 patients on Schedule A (10 or 15 mg oral entinostat once every other week); 16 patients on Schedule B (15 mg oral entinostat once weekly in 3 of 4 weeks). Patients received a median of 3 prior treatments (range 1-10), with 80% of the patients receiving a prior stem cell transplant and 8% of patients receiving prior brentuximab vedotin. In the intention-to-treat analysis, the overall response rate was 12% while the disease control rate (complete response, partial response, and stable disease beyond 6 months) was 24%. Seven patients did not complete the first cycle due to progression of disease. Tumor reduction was observed in 24 of 38 (58%) evaluable patients. Median progression-free survival and overall survival was 5.5 and 25.1 months, respectively. The most frequent grade 3 or 4 adverse events were thrombocytopenia (63%), anemia (47%), neutropenia (41%), leukopenia (10%), hypokalemia (8%), and hypophosphatemia (6%). Twenty-five (51%) patients required dose-reductions or delays. Pericarditis/pericardial effusion occurred in one patient after 12 cycles of therapy. Future studies are warranted to identify predictive biomarkers for treatment response and to develop mechanism-based combination strategies. (clinicaltrials.gov identifier:00866333)